Suppliers and packagers for nitisinone

nitisinone

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eton	NITISINONE	nitisinone	CAPSULE;ORAL	216201	ANDA	Eton Pharmaceuticals, Inc.	71863-119-60	1 BOTTLE in 1 CARTON (71863-119-60) / 60 CAPSULE in 1 BOTTLE	2024-01-15
Eton	NITISINONE	nitisinone	CAPSULE;ORAL	216201	ANDA	Eton Pharmaceuticals, Inc.	71863-120-60	1 BOTTLE in 1 CARTON (71863-120-60) / 60 CAPSULE in 1 BOTTLE	2024-01-15
Eton	NITISINONE	nitisinone	CAPSULE;ORAL	216201	ANDA	Eton Pharmaceuticals, Inc.	71863-121-60	1 BOTTLE in 1 CARTON (71863-121-60) / 60 CAPSULE in 1 BOTTLE	2024-01-15
Eton	NITISINONE	nitisinone	CAPSULE;ORAL	216201	ANDA	Eton Pharmaceuticals, Inc.	71863-122-60	1 BOTTLE in 1 CARTON (71863-122-60) / 60 CAPSULE in 1 BOTTLE	2024-01-15
Medunik	NITISINONE	nitisinone	CAPSULE;ORAL	212390	ANDA	Analog Pharma	70505-202-60	1 BOTTLE, PLASTIC in 1 CARTON (70505-202-60) / 60 CAPSULE in 1 BOTTLE, PLASTIC	2022-06-15
Medunik	NITISINONE	nitisinone	CAPSULE;ORAL	212390	ANDA	Analog Pharma	70505-205-60	1 BOTTLE, PLASTIC in 1 CARTON (70505-205-60) / 60 CAPSULE in 1 BOTTLE, PLASTIC	2022-06-15

Nitisinone Supplier Landscape Analysis

Last updated: February 19, 2026

Nitisinone, a tyrosine aminotransferase inhibitor, is critical for treating hereditary tyrosinemia type 1 (HT-1), a rare genetic disorder. The global supply chain for nitisinone is concentrated among a limited number of manufacturers, impacting accessibility and pricing. This analysis examines the current suppliers, their manufacturing capabilities, regulatory standing, and potential market dynamics.

What is the Global Supply of Nitisinone?

The production of nitisinone is primarily controlled by a small cohort of Active Pharmaceutical Ingredient (API) manufacturers. These entities possess the specialized technical expertise and regulatory approvals necessary for its synthesis. Key players in the nitisinone API market include:

• Albany Molecular Research Inc. (AMRI): AMRI is a significant contract development and manufacturing organization (CDMO) that has been involved in the production of nitisinone. They operate multiple facilities with cGMP (current Good Manufacturing Practice) compliance. Their capacity and specific role in the current supply chain require direct inquiry. [1]
• Shandong Xinhua Pharmaceutical Co., Ltd.: This Chinese pharmaceutical company is a known producer of various APIs, including nitisinone. They have established manufacturing sites and export products globally. Their regulatory filings indicate production capabilities for nitisinone. [2]
• Various Indian API Manufacturers: Several Indian pharmaceutical companies are reported to produce nitisinone, though specific names and their current production status are less publicly documented. These companies typically operate under strict regulatory oversight, including FDA inspections for products intended for the U.S. market. Examples might include companies with broad steroid and heterocyclic compound synthesis expertise.

The global demand for nitisinone is relatively low due to the rarity of HT-1. However, the specialized nature of its synthesis and the stringent regulatory requirements for pharmaceutical APIs create barriers to entry for new suppliers.

What are the Regulatory Considerations for Nitisinone Suppliers?

Regulatory compliance is paramount for all nitisinone API manufacturers. Suppliers must adhere to cGMP standards as mandated by major health authorities like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

• FDA Approval: Manufacturers supplying nitisinone for the U.S. market must have their facilities inspected and approved by the FDA. Drug Master Files (DMFs) are typically filed with the FDA to provide detailed information about the manufacturing process, quality control, and stability of the API.
• EMA Certification: For the European Union market, API manufacturers must comply with EMA guidelines and obtain Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) or equivalent documentation demonstrating compliance.
• Other Health Authorities: Suppliers catering to other international markets must meet the specific regulatory requirements of those countries. This often involves site inspections and the submission of comprehensive documentation.

The limited number of approved suppliers means that any disruption in production or regulatory non-compliance at one of these facilities can significantly impact global supply availability.

How Does Nitisinone Manufacturing Differ from Standard APIs?

The synthesis of nitisinone involves complex chemical processes that distinguish it from many other common pharmaceutical APIs.

• Chemical Structure: Nitisinone (chemical name: 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione) is a synthetic derivative of homogentisic acid. Its molecular structure is:
  • Molecular Formula: C14H10F3NO4
  • Molecular Weight: 329.23 g/mol [3]
• Synthesis Pathway: The manufacturing process typically involves multi-step organic synthesis. Key intermediates and reagents may include:
  • Trifluoromethylbenzoyl derivatives
  • Cyclohexane-1,3-dione derivatives
  • Nitration reagents The specific reaction conditions, purification methods, and quality control measures are critical to ensure the purity and efficacy of the final API. These processes often require specialized equipment and expertise in handling hazardous chemicals.
• Quality Control: Rigorous analytical testing is required to confirm identity, purity, and potency. This includes:
  • High-Performance Liquid Chromatography (HPLC) for impurity profiling.
  • Mass Spectrometry (MS) for structural confirmation.
  • Nuclear Magnetic Resonance (NMR) spectroscopy for detailed structural analysis.
  • Residual solvent analysis.
  • Heavy metal testing.

The complexity of the synthesis and the stringent quality requirements necessitate significant investment in research and development, process optimization, and analytical capabilities, further concentrating production among experienced manufacturers.

What is the Market Structure for Nitisinone API?

The market for nitisinone API is characterized by a monopolistic or oligopolistic structure due to the niche therapeutic indication and high manufacturing barriers.

• Limited Number of Suppliers: As previously noted, only a few companies globally can reliably produce GMP-grade nitisinone. This limited competition can lead to higher pricing.
• Price Sensitivity: While the patient population is small, the cost of nitisinone is substantial. The price is influenced by manufacturing costs, regulatory compliance expenses, and the lack of alternative treatments. Orphan drug designations often provide market exclusivity that can influence pricing.
• Supply Chain Vulnerability: The concentrated nature of the supply chain makes it susceptible to disruptions. Factors such as geopolitical instability, raw material shortages, manufacturing site issues, or regulatory actions against a key supplier can lead to shortages.
• Role of Branded vs. Generic: Nitisinone is primarily marketed under brand names (e.g., Orfadin). The availability of generic nitisinone API is dependent on the ability of other manufacturers to develop and gain regulatory approval for their own API production, which is a lengthy and costly process.
• Contract Manufacturing: Many finished drug product manufacturers rely on API suppliers through contracts. These agreements are crucial for ensuring a stable supply and often involve long-term commitments.

Who are the Major Finished Drug Product Manufacturers of Nitisinone?

The finished drug product containing nitisinone is primarily manufactured and marketed by a few pharmaceutical companies.

• Swedish Orphan Biovitrum AB (Sobi): Sobi is the primary marketer of Orfadin®, the most widely recognized brand of nitisinone. Sobi acquired the rights to Orfadin from earlier developers and has maintained its market presence. Their supply chain relies on contracted API manufacturers. [4]
• Other Generic Formulators: While Sobi holds significant market share, the potential for generic competition exists once patents expire and alternative API sources are validated. Companies specializing in the development of generics for rare diseases may enter this market. Information on specific generic manufacturers currently producing nitisinone finished products is limited due to the niche market and proprietary formulations.

The collaboration between API suppliers and finished drug product manufacturers is essential for the consistent availability of nitisinone to patients.

What are the Challenges in Securing a Reliable Nitisinone Supply?

Several factors contribute to the challenges in ensuring a consistent and affordable supply of nitisinone.

• Rarity of Indication: Hereditary tyrosinemia type 1 (HT-1) is an ultra-rare disease, affecting approximately 1 in 100,000 live births worldwide. This small patient population means that the overall market demand for nitisinone is low, making it less attractive for large-scale, diversified API manufacturers to enter the market.
• High Cost of Production: The complex multi-step synthesis, stringent quality control requirements, and the need for specialized equipment and expertise contribute to high manufacturing costs.
• Regulatory Hurdles: Obtaining and maintaining regulatory approval from agencies like the FDA and EMA for both the API and the finished drug product is a significant undertaking. This includes rigorous validation of manufacturing processes, impurity profiles, and stability studies.
• Limited Number of Approved Suppliers: The concentration of manufacturing capabilities among a few companies creates a bottleneck. Any operational issue at one of these facilities can lead to a global shortage.
• Supply Chain Disruptions: Like any pharmaceutical supply chain, nitisinone is vulnerable to disruptions from raw material availability, geopolitical events, natural disasters, or unexpected plant shutdowns.
• Pricing and Market Exclusivity: As an orphan drug, nitisinone often benefits from market exclusivity periods, which can contribute to its high price. This can limit the economic incentives for additional manufacturers to invest in developing alternative supply chains.

What is the Future Outlook for Nitisinone Suppliers?

The future of nitisinone supply is likely to remain concentrated, with potential for incremental changes.

• Continued Reliance on Existing Manufacturers: For the foreseeable future, the existing core group of nitisinone API manufacturers is expected to continue supplying the market. Their established regulatory status and manufacturing infrastructure provide a stable, albeit limited, supply base.
• Potential for New Entrants: While barriers are high, the development of new synthesis routes or improvements in existing processes could potentially lower manufacturing costs and attract new API manufacturers, particularly from regions with strong generic API sectors like India and China. However, gaining regulatory approval for these new suppliers is a significant hurdle.
• Increased Scrutiny on Supply Chain Resilience: Given the critical nature of nitisinone for patients with HT-1, there will likely be increased focus from regulatory bodies and patient advocacy groups on the resilience and security of the supply chain. This could drive initiatives for dual sourcing and enhanced risk management by finished product manufacturers.
• Impact of Biosimil/Generic Entry: The entry of generic nitisinone finished products, contingent on successful API sourcing and regulatory approval, could introduce more competition. This would depend on the ability of generic API manufacturers to meet the stringent quality standards and cost-effectively compete.
• Technological Advancements: Innovations in chemical synthesis and process analytical technology (PAT) could potentially streamline nitisinone production, making it more efficient and potentially more accessible.

Key Takeaways

The global supply of nitisinone is characterized by a concentrated landscape of specialized API manufacturers, primarily serving the ultra-rare disease indication of hereditary tyrosinemia type 1. Key suppliers include AMRI and Shandong Xinhua Pharmaceutical, alongside a less publicly detailed network of Indian manufacturers. Regulatory compliance, including cGMP standards and FDA/EMA approvals, is a critical barrier to entry. The complex chemical synthesis of nitisinone further limits the number of producers. The market is largely controlled by branded product manufacturers like Sobi, with pricing influenced by manufacturing costs and orphan drug status. Challenges to supply reliability stem from the rarity of the indication, high production costs, stringent regulations, and the inherent vulnerabilities of a concentrated supply chain. The future outlook suggests continued reliance on existing suppliers, with potential for new entrants contingent on overcoming significant regulatory and technical hurdles, and an increasing emphasis on supply chain resilience.

FAQs

1. Are there any shortages of nitisinone currently reported globally? Specific real-time shortage data is dynamic and best obtained through official regulatory agency notifications (e.g., FDA Drug Shortages Program, EMA) and direct communication with drug product manufacturers. Historical data indicates that intermittent supply concerns can arise due to the specialized manufacturing.
2. What are the typical lead times for ordering nitisinone API from a manufacturer? Lead times can vary significantly depending on the manufacturer's production schedule, existing inventory, and the quantity ordered. For specialized APIs like nitisinone, lead times can range from several weeks to months, often requiring advance planning and commitment.
3. Does the patent status of nitisinone affect the availability of generic API? Yes, patent expiry is a prerequisite for generic manufacturers to enter the market. However, even after patent expiry, generic API manufacturers must successfully navigate the complex regulatory approval process, including demonstrating bioequivalence and meeting all quality standards.
4. Can a new pharmaceutical company easily become a nitisinone API supplier? No, it is exceptionally difficult for a new company to become a nitisinone API supplier. The process involves substantial investment in specialized chemical synthesis expertise, state-of-the-art manufacturing facilities compliant with cGMP, and a rigorous, multi-year regulatory approval process with global health authorities.
5. How does the price of nitisinone API compare to more common pharmaceutical APIs? Nitisinone API is significantly more expensive than APIs for widely used drugs. This higher cost is attributable to the low patient volume, complex and low-yield synthesis processes, high regulatory compliance burden, and the specialized nature of the treatment.

Citations

[1] Albany Molecular Research Inc. (n.d.). API Manufacturing. Retrieved from https://www.amriglobal.com/capabilities/api-manufacturing/

[2] Shandong Xinhua Pharmaceutical Co., Ltd. (n.d.). API Products. Retrieved from https://www.xhpharm.com/ (Specific product lists may require direct access to company portals or databases)

[3] PubChem. (n.d.). Nitisinone. National Center for Biotechnology Information. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Nitisinone

[4] Swedish Orphan Biovitrum AB. (n.d.). Orfadin®. Retrieved from https://www.sobi.com/ (Product information typically found within company drug portfolios)